Formycon (FYB.DE) Stock Price

Formycon Price

XETRA·CLOSED
18.60EUR-0.66 (-3.49 %)
Market closed

Revenue has compounded at 61.9% per year over the past 16 years to 44.48 M EUR. Earnings per share have grown at 54.8% per year over the last 9 years. Formycon's net margin stands at -145.5%, down from -36.3% several years earlier. Analysts set a median price target of 40.80 EUR, implying 119.4% above the current price. Of 13 analysts, 11 rate the stock a buy — an overall Buy consensus. The stock trades about 11% above its 52-week low.

Formycon stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Formycon over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Formycon stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Formycon's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Formycon Stock Price History
DateFormycon Price
8/5/202618.60 EUR
8/4/202619.26 EUR
7/31/202619.18 EUR
7/30/202618.90 EUR
7/29/202618.94 EUR
7/28/202618.72 EUR
7/27/202618.82 EUR
7/24/202618.88 EUR
7/23/202618.58 EUR
7/22/202618.78 EUR
7/21/202618.60 EUR
7/20/202618.04 EUR
7/17/202617.70 EUR
7/16/202617.94 EUR
7/15/202618.16 EUR
7/14/202618.26 EUR
7/13/202618.22 EUR
7/10/202618.80 EUR
7/9/202619.00 EUR
7/8/202618.30 EUR
7/7/202618.70 EUR
7/6/202619.32 EUR
7/3/202619.36 EUR
7/2/202619.68 EUR
7/1/202619.10 EUR
6/30/202619.70 EUR
6/29/202619.02 EUR
6/26/202618.88 EUR
6/25/202619.28 EUR
6/24/202619.94 EUR
6/23/202620.35 EUR
6/22/202619.60 EUR
6/19/202619.66 EUR
6/18/202620.00 EUR
6/17/202620.15 EUR
6/16/202620.40 EUR
6/15/202621.25 EUR
6/12/202620.95 EUR
6/11/202619.76 EUR
6/10/202619.98 EUR
6/9/202620.10 EUR
6/8/202620.10 EUR
6/5/202620.65 EUR
6/4/202620.70 EUR
6/3/202620.05 EUR
6/2/202621.50 EUR
6/1/202622.05 EUR
5/29/202622.60 EUR
5/28/202621.30 EUR
5/27/202620.25 EUR
5/26/202620.00 EUR
5/25/202620.80 EUR
5/22/202620.05 EUR
5/21/202619.66 EUR
5/20/202620.80 EUR
5/19/202618.18 EUR
5/18/202618.70 EUR
5/15/202618.88 EUR
5/14/202618.96 EUR
5/13/202619.16 EUR
5/12/202618.30 EUR
5/11/202619.06 EUR
5/8/202618.80 EUR
5/7/202619.46 EUR
5/6/202618.56 EUR
5/5/202617.94 EUR
5/4/202617.92 EUR
4/30/202618.10 EUR
4/29/202617.88 EUR
4/28/202618.02 EUR
4/27/202617.92 EUR
4/24/202618.30 EUR
4/23/202619.06 EUR
4/22/202618.30 EUR
4/21/202619.06 EUR
4/20/202618.98 EUR
4/17/202619.82 EUR
4/16/202618.78 EUR
4/15/202618.56 EUR
4/14/202618.56 EUR
4/13/202617.82 EUR
4/10/202617.72 EUR
4/9/202617.86 EUR
4/8/202618.84 EUR
4/7/202617.76 EUR
4/2/202618.62 EUR
4/1/202618.96 EUR
3/31/202618.00 EUR
3/30/202618.02 EUR
3/27/202617.66 EUR
3/26/202617.82 EUR
3/25/202618.56 EUR
3/24/202617.10 EUR
3/23/202617.28 EUR
3/20/202617.06 EUR
3/19/202616.82 EUR
3/18/202619.82 EUR
3/17/202619.84 EUR
3/16/202619.32 EUR
3/13/202618.88 EUR
3/12/202619.28 EUR
3/11/202619.72 EUR
3/10/202620.20 EUR
3/9/202619.16 EUR
3/6/202619.74 EUR
3/5/202619.68 EUR
3/4/202621.95 EUR
3/3/202621.40 EUR
3/2/202622.35 EUR
2/27/202622.95 EUR
2/26/202622.85 EUR
2/25/202622.65 EUR
2/24/202620.80 EUR
2/23/202621.25 EUR
2/20/202622.95 EUR
2/19/202623.20 EUR
2/18/202623.65 EUR
2/17/202623.80 EUR
2/16/202623.35 EUR
2/13/202623.80 EUR
2/12/202623.60 EUR
2/11/202623.95 EUR
2/10/202623.50 EUR
2/9/202623.25 EUR
2/6/202623.00 EUR
2/5/202622.80 EUR
2/4/202623.05 EUR
2/3/202623.25 EUR
2/2/202622.85 EUR
1/30/202623.00 EUR
1/29/202622.90 EUR
1/28/202622.90 EUR
1/27/202623.45 EUR
1/26/202623.30 EUR
1/23/202623.70 EUR
1/22/202624.00 EUR
1/21/202623.25 EUR
1/20/202623.05 EUR
1/19/202623.15 EUR
1/16/202624.05 EUR
1/15/202624.20 EUR
1/14/202625.30 EUR
1/13/202625.85 EUR
1/12/202625.40 EUR
1/9/202625.80 EUR
1/8/202625.90 EUR
1/7/202625.75 EUR
1/6/202625.45 EUR
1/5/202625.35 EUR
1/2/202626.10 EUR
12/30/202525.60 EUR
12/29/202525.35 EUR
12/23/202524.85 EUR
12/22/202524.40 EUR
12/19/202523.70 EUR
12/18/202523.65 EUR
12/17/202523.65 EUR
12/16/202523.65 EUR
12/15/202523.65 EUR
12/12/202523.65 EUR
12/11/202523.65 EUR
12/10/202523.10 EUR
12/9/202524.00 EUR
12/8/202524.90 EUR
12/5/202524.95 EUR
12/4/202525.75 EUR
12/3/202523.30 EUR
12/2/202522.85 EUR
12/1/202523.10 EUR
11/28/202524.25 EUR
11/27/202524.60 EUR
11/26/202523.95 EUR
11/25/202523.95 EUR
11/24/202523.15 EUR
11/21/202523.15 EUR
11/20/202523.30 EUR
11/19/202523.30 EUR
11/18/202522.35 EUR
11/17/202523.25 EUR
11/14/202520.75 EUR
11/13/202521.60 EUR
11/12/202521.60 EUR
11/11/202520.35 EUR
11/10/202520.35 EUR
11/7/202520.20 EUR
11/6/202520.20 EUR
11/5/202520.00 EUR
11/4/202521.15 EUR
11/3/202521.20 EUR
10/31/202521.90 EUR
10/30/202522.10 EUR
10/29/202522.40 EUR
10/28/202522.85 EUR
10/27/202522.85 EUR
10/24/202522.55 EUR
10/23/202523.10 EUR
10/22/202523.35 EUR
10/21/202523.85 EUR
10/20/202523.75 EUR
10/17/202523.30 EUR
10/16/202524.10 EUR
10/15/202523.55 EUR
10/14/202523.45 EUR
10/13/202524.30 EUR
10/10/202524.60 EUR
10/9/202525.30 EUR
10/8/202525.40 EUR
10/7/202525.40 EUR
10/6/202525.35 EUR
10/3/202525.35 EUR
10/2/202525.35 EUR
10/1/202522.95 EUR
9/30/202522.50 EUR
9/29/202522.50 EUR
9/26/202522.10 EUR
9/25/202522.55 EUR
9/24/202523.30 EUR
9/23/202523.40 EUR
9/22/202523.35 EUR
9/19/202523.35 EUR
9/18/202522.95 EUR
9/17/202522.45 EUR
9/16/202521.70 EUR
9/15/202521.55 EUR
9/12/202522.20 EUR
9/11/202522.25 EUR
9/10/202522.80 EUR
9/9/202522.90 EUR
9/8/202523.30 EUR
9/5/202523.55 EUR
9/4/202523.15 EUR
9/3/202523.20 EUR
9/2/202524.00 EUR
9/1/202524.80 EUR
8/29/202524.15 EUR
8/28/202524.60 EUR
8/27/202524.10 EUR
8/26/202524.05 EUR
8/25/202524.60 EUR
8/22/202524.50 EUR
8/21/202524.15 EUR
8/20/202524.60 EUR
8/19/202524.95 EUR
8/18/202525.00 EUR
8/15/202525.00 EUR
8/14/202525.00 EUR
8/13/202525.00 EUR
8/12/202525.00 EUR
8/11/202525.00 EUR
8/8/202525.80 EUR
8/7/202525.25 EUR
Access this data via the Eulerpool API
Get Free API Key

Formycon Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
42.50 M EUR
-17.73 M EUR
35.99 M EUR
Jan 1, 2023
77.70 M EUR
-369,000.00 EUR
75.80 M EUR
Jan 1, 2024
69.67 M EUR
-23.54 M EUR
-125.67 M EUR
Jan 1, 2025
44.48 M EUR
-29.37 M EUR
-64.70 M EUR
Jan 1, 2026 (e)
72.73 M EUR
-548,128.00 EUR
-21.76 M EUR
Jan 1, 2027 (e)
121.35 M EUR
-840,948.00 EUR
19.42 M EUR
Jan 1, 2028 (e)
107.00 M EUR
-933,417.00 EUR
9.45 M EUR
Jan 1, 2029 (e)
159.66 M EUR
-1.39 M EUR
53.52 M EUR

Formycon Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 6, 2026, 12:16 PM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
SHARESM
2014201520162017201820192020202120222023202420252026e2027e2028e2029e
12.0016.0019.0029.0042.0033.0034.0036.0042.0077.0069.0044.0072.00121.00107.00159.00
–33.3318.7552.6344.83-21.433.035.8816.6783.33-10.39-36.2363.6468.06-11.5748.60
50.0050.0021.0527.5942.869.09-5.8827.7828.5729.8720.296.826.826.826.826.82
6.008.004.008.0018.003.00-2.0010.0012.0023.0014.003.004.918.257.3010.84
––-4.00-1.007.00-2.00-6.00-14.00-17.00–-23.00-29.00–––-1.00
––-21.05-3.4516.67-6.06-17.65-38.89-40.48–-33.33-65.91–––-0.63
––-4.00-1.007.00-2.00-6.00-13.0035.0075.00-125.00-64.00-21.0019.009.0053.00
–––-75.00-800.00-128.57200.00116.67-369.23114.29-266.67-48.80-67.19-190.48-52.63488.89
9.318.859.129.599.5010.0011.0011.0615.1316.0417.6617.6617.6617.6617.6617.66
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Formycon generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Formycon retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Formycon's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Formycon has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Formycon's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Formycon stock margins

The Formycon margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Formycon. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Formycon.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
27.61 %
-38.36 %
-36.30 %
Jan 1, 2022
28.41 %
-41.72 %
84.69 %
Jan 1, 2023
30.00 %
-0.47 %
97.55 %
Jan 1, 2024
21.29 %
-33.79 %
-180.37 %
Jan 1, 2025
8.04 %
-66.03 %
-145.46 %
Jan 1, 2026 (e)
8.04 %
-0.75 %
-29.91 %
Jan 1, 2027 (e)
8.04 %
-0.69 %
16.01 %
Jan 1, 2028 (e)
8.04 %
-0.87 %
8.83 %

Formycon Stock Revenue, EBIT, Earnings per Share

The Formycon earnings per share therefore indicates how much revenue Formycon has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
3.31 EUR
-1.27 EUR
-1.20 EUR
Jan 1, 2022
2.81 EUR
-1.17 EUR
2.38 EUR
Jan 1, 2023
4.84 EUR
-0.02 EUR
4.73 EUR
Jan 1, 2024
3.94 EUR
-1.33 EUR
-7.11 EUR
Jan 1, 2025
2.52 EUR
-1.66 EUR
-3.66 EUR
Jan 1, 2026 (e)
4.16 EUR
-0.03 EUR
-1.24 EUR
Jan 1, 2027 (e)
6.94 EUR
-0.05 EUR
1.11 EUR
Jan 1, 2028 (e)
6.12 EUR
-0.05 EUR
0.54 EUR

Formycon business model & stock analysis

Formycon AG is a German biotechnology company that was founded in 2010 in Martinsried near Munich. The company's history mainly began with the development of an innovative technology concept that allows for the cost-effective and efficient production of biosimilars. The market entry started in 2017 with the launch of the first proprietary biosimilar on the European market. The core business of Formycon AG is the production and distribution of biosimilars. These are biological drugs that have a similar structure and efficacy to already approved original drugs. The development of biosimilars is complex due to the elaborate manufacturing process and high-quality assurance requirements, requiring innovative ideas and technologies. Formycon AG has developed its innovative platform technology, FORMYCON® NEXT LEVEL, which allows the company to cost-effectively produce large quantities of proteins used in cancer therapy, immunotherapy, and the treatment of autoimmune diseases. Formycon AG is divided into various divisions, including research and development, production, and distribution. In research and development, new biosimilars and other innovative technologies are developed to further improve production processes. Production takes place in a dedicated biotechnological production facility in Roth near Nuremberg, where up to eight different medications can be produced simultaneously. In the distribution sector, Formycon AG collaborates with partners who market and distribute the biosimilars in different countries. The company operates internationally, with a presence in Europe, the USA, and Asia. The biosimilars produced by Formycon AG are a cost-effective alternative to the existing original drugs. The products are used in the fields of oncology, immunology, and ophthalmology, offering patients a chance to receive effective therapy at an affordable price. Successful marketing and high demand contribute to positive company development. In 2020, Formycon AG generated a revenue of 25 million euros and currently employs approximately 150 staff members. An example of a biosimilar produced by Formycon AG is the drug FYB202, which is used for the treatment of breast, ovarian, and salivary gland cancer. It is a replica of the breast cancer medication Herceptin®, developed and distributed by the Swiss company Roche. The FYB202 biosimilar has shown in clinical studies that it is similarly effective as Herceptin® but represents a more cost-effective alternative for patients. Overall, Formycon AG pursues a sustainable business model with a focus on the development of cost-effective biosimilars. The innovative technology and focus on cost-effective production enable the company to achieve a strong market presence and offer an effective alternative to conventional drugs.

Formycon SWOT Analysis

Strengths

Formycon AG has a strong portfolio of biosimilar products, positioning itself as a key player in the pharmaceutical industry.

The company's partnerships with major pharmaceutical companies provide it with access to resources, expertise, and distribution channels.

Formycon AG has a robust research and development pipeline, constantly working on innovative solutions and enhancing its product offerings.

Weaknesses

The company heavily relies on its partnerships, making it susceptible to changes in business relationships and potential dependency.

Formycon AG may face challenges in obtaining regulatory approvals for its biosimilar products, which can lead to delays and increased costs.

The company's limited marketing and promotional activities may hinder its ability to fully exploit market opportunities.

Opportunities

The increasing demand for affordable healthcare and cost-effective treatment options creates significant opportunities for Formycon AG's biosimilars.

Expansion into new markets and regions presents the company with the chance to diversify its revenue streams and strengthen its global presence.

Strategic collaborations with emerging biotechnology companies can facilitate knowledge exchange and open doors to new research and development opportunities.

Threats

Intense competition from rival companies operating in the biosimilars market poses a threat to Formycon AG's market share and potential profitability.

Changes in healthcare regulations and pricing policies can impact the reimbursement rates and financial viability of the company's products.

Emerging technologies or alternative treatment options could disrupt the demand for Formycon AG's biosimilars.

Formycon Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Formycon historical P/E ratio, EBIT multiple, and P/S ratio

Formycon annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Formycon shares outstanding

The number of shares of Formycon was 17.66 M in 2025. This indicates how many shares Formycon is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
11.06 M Stocks
Jan 1, 2022
15.13 M Stocks
Jan 1, 2023
16.04 M Stocks
Jan 1, 2024
17.66 M Stocks
Jan 1, 2025
17.66 M Stocks
Jan 1, 2026 (e)
17.66 M Stocks
Jan 1, 2027 (e)
17.66 M Stocks
Jan 1, 2028 (e)
17.66 M Stocks

Current Formycon forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
84.62 % (11)
Hold
15.38 % (2)
Sell
0.00 % (0)
12M Price Target
40.80
Last Price
18.60
Currency
EUR
12M Return Potential
119.35 %
LTM Return
0 %

Formycon shareholder structure

% Name
0.45736%
ACATIS Investment Kapitalverwaltungsgesellschaft GmbH
ACATIS Investment Kapitalverwaltungsgesellschaft GmbH
0.27462%
BlackRock Asset Management Deutschland AG
BlackRock Asset Management Deutschland AG
0.27340%
Amundi Asset Management, SAS
Amundi Asset Management, SAS
0.25084%
Paladin Asset Management Investmentaktiengesellschaft TGV
Paladin Asset Management Investmentaktiengesellschaft TGV
0.18580%
GS&P Kapitalanlagegesellschaft S.A.
GS&P Kapitalanlagegesellschaft S.A.
0.17151%
MFI Asset Management GmbH
MFI Asset Management GmbH

Formycon Beneficial Ownership Filings (SEC 13D/G)

Free Float
45.3%
Float Shares
-
Shares Outstanding
-

Formycon Executives and Management Board

10 members · avg. age 55 · 20 % women

SG

Dr. Stefan Glombitza

Chief Executive Officer, Member of the Executive Board

612,300.00 EUR

Management

ES

Mr. Enno Spillner

Chief Financial Officer, Member of the Executive Board

560,900.00 EUR
NM

Ms. Nicola Mikulcik

Member of the Executive Board, Chief Business Officer

393,800.00 EUR
AS

Dr. Andreas Seidl

Chief Scientific Officer, Member of the Executive Board

339,500.00 EUR

Board of Directors

WE

Mr. Wolfgang Essler (52)

Chairman of the Supervisory Board · since 2023

67,800.00 EUR
KR

Mr. Klaus Roehrig (47)

Member of the Supervisory Board

39,000.00 EUR
NH

Mr. Nicholas Haggar (60)

Independent Member of the Supervisory Board · since 2024

35,800.00 EUR
BC

Dr. Bodo Coldewey (53)

Independent Member of the Supervisory Board

29,300.00 EUR
CB

Mr. Colin Bond (64)

Independent Deputy Chairman of Supervisory Board · since 2024

22,500.00 EUR
SM

Ms. Sabrina Mueller

Director Investor Relations and Corporate Communications · since 2025

–

Formycon Supply Chain

Formycon Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
1 companies
#NameTrend
1
Teva Pharmaceutical Inds
Customer·IL
0.88
0.48
0.53
0.43
0.23
0.06

Frequently asked questions about Formycon

The business model of Formycon AG is focused on the development and commercialization of high-quality biosimilar medicines. As a biopharmaceutical company, Formycon specializes in the production of affordable and safe alternatives to expensive biological drugs. By leveraging its proprietary technology and extensive expertise, Formycon aims to address unmet medical needs and improve patient access to therapies. The company collaborates with strategic partners to carry out the research, development, and clinical trials required for regulatory approval. Through its commitment to innovation and cost-effectiveness, Formycon AG strives to contribute to the betterment of healthcare systems worldwide.

Formycon AG is primarily active in the pharmaceutical industry.

The main competitors of Formycon AG in the market include major pharmaceutical companies such as Novartis, Pfizer, Roche, and Sanofi.

Formycon AG is a renowned biopharmaceutical company based in Germany. Established in 2010, the company specializes in the development and production of biosimilars, which are biological drugs highly similar to existing approved products. As a significant player in the industry, Formycon AG aims to make healthcare more affordable and accessible by providing cost-effective biosimilar solutions. The company's expertise lies in the fields of rheumatology, ophthalmology, and oncology, among others. With a strong commitment to research and innovation, Formycon AG has successfully built a robust pipeline of biosimilar candidates and established partnerships with major pharmaceutical companies.

Formycon AG, a renowned pharmaceutical company, has achieved several significant milestones. Notably, the company has successfully developed and commercialized cost-effective biosimilar medicines for various diseases. Formycon AG has gained regulatory approvals for several products, including biosimilar candidates for eye diseases, such as ranibizumab and aflibercept. Moreover, the company has entered into strategic partnerships with prominent pharmaceutical companies, expanding its global reach and market presence. Formycon AG's commitment to innovation and extensive research has driven its success in delivering high-quality and affordable treatments. With its steadfast dedication, Formycon AG continues to redefine healthcare standards and improve patient access to life-saving medications.

Formycon AG is primarily present in Germany, where it is headquartered. As a leading biopharmaceutical company, Formycon operates in various regions across the globe. However, its primary focus remains on the German market, leveraging its expertise in biosimilar drugs. With a strong presence in Germany, Formycon AG aims to contribute to the development and accessibility of high-quality and affordable medicines for patients.

Formycon AG represents values of innovation, excellence, and sustainability in the pharmaceutical industry. Committed to advancing biosimilar drug development, Formycon AG focuses on enhancing patient access to affordable treatments. The company strives to create high-quality and safe biosimilars, providing patients with effective alternatives to expensive originator drugs. Formycon AG's corporate philosophy is rooted in their dedication to delivering high-value propositions that benefit both patients and healthcare systems. By leveraging their expertise in molecular biology and biotechnology, Formycon AG aims to address the unmet medical needs and improve the quality of life for patients worldwide.

Analysts currently set an average price target of 50.43 EUR for the Formycon stock (median: 40.80 EUR), implying +171.1 % versus the latest price. The consensus is based on 13 analyst ratings.

Formycon Analyst Price Targets 2026

13 analysts currently rate the Formycon stock: 11 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Formycon to generate revenue of 72.73 M EUR and earnings per share of -1.23 EUR.

Formycon Analyst Price Targets 2026

The Formycon share (FYB.DE) is listed on 8 stock exchanges, including: XETRA (FYB.DE), Frankfurt (FYB.F), München (FYB.MU), Düsseldorf (FYB.DU), Hamburg (FYB.HM), London (0W4N.L), London (0W4N.L), SIX (Zürich) (FYB.SW).

The Formycon AG is a biotechnology company specializing in biosimilars. Their business model is to offer more affordable versions of biotechnologically manufactured medicines already on the market. Biosimilars are biologically produced medicines that have similar active ingredients to already approved original preparations and have the same therapeutic effect. The company specializes in developing biosimilars for various therapy areas such as oncology, rheumatology, ophthalmology, and neurology. They focus particularly on established brand products with high value potential. The company conducts research and development in collaboration with partners and clients from the pharmaceutical industry and utilizes its biotechnology expertise in areas such as cell line development, fermentation processes, and the purification of active ingredients. In addition to development, the company aims to successfully market its biosimilars by partnering with established pharmaceutical companies for global distribution channels and rapid entry into key markets. The Formycon AG is currently working on several biosimilars in different stages of clinical development. They also offer consulting services related to biosimilars, leveraging their extensive biotechnology knowledge to support customers in bringing biosimilars to market. In summary, Formycon AG offers a comprehensive range of services including biosimilar development, marketing and distribution support, and biotechnology consulting. Through their focus on biosimilars and partnerships with established pharmaceutical companies, they can quickly and successfully enter the market and establish themselves as a leading provider.

The expected revenue of Formycon is 72.73 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Formycon is -21.76 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Formycon is currently -15.10. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Formycon stock.

The price-to-sales ratio (P/S) of Formycon is currently 4.52. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Formycon stock.

The Eulerpool Quality Score for Formycon is 2/10.

The ISIN of Formycon is DE000A1EWVY8. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Formycon is A1EWVY. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Formycon is FYB.DE. The ticker symbol is used to trade Formycon shares on the stock exchange.

Formycon paid dividends every year for the past 0 years.

Formycon is assigned to the 'Health' sector.

The dividends of Formycon are distributed in EUR.

All fundamentals and in-depth analysis of Formycon

Our stock analysis for Formycon stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Formycon. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Formycon Stock
Formycon Revenue→
Formycon Stock
Formycon Net Income→
Formycon Stock
Formycon P/E→
Formycon Stock
Formycon P/S→
Formycon Stock
Formycon EBIT→
Formycon Stock
Formycon Dividend→
Formycon Stock
Formycon Directors Dealings→
Formycon Stock
Formycon Stocks→
Formycon Stock
Formycon Market capitalization→
Formycon Stock
Formycon Debt→
Formycon Stock
Formycon Liabilities→
Formycon Stock
Formycon Equity→
Formycon Stock
Formycon AAQS→
Formycon Stock
Formycon Employees→
Formycon Stock
Formycon ROE→
Formycon Stock
Formycon ROA→
Formycon Stock
Formycon ROCE→
Formycon Stock
Formycon News→
Formycon Stock
Formycon Analyst Price Targets→

Health Stocks

Forte BiosciencesFormosa PharmaceuticalsFortis HealthcareFormosa LaboratoriesFortis Malar HospitalsForesee Pharmaceuticals CoFortrea HoldingsFoghorn TherapeuticsFortress BiotechFluoroPharma MedicalForza InnovationsFluoguide ASAll Stocks A–Z →